Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 3

TABLE OF CONTENTS
March 2015 Volume 12 Number 3
Impact Factor15.696 *	In this issue Research Highlights News and Views Correction Reviews Also this month  Featured article: Management of locally advanced breast cancer—perspectives and future directions Konstantinos Tryfonidis, Elzbieta Senkus, Maria J. Cardoso & Fatima Cardoso
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Open for Submissions Molecular Therapy — Oncolytics is an online-only, open access journal, focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. Explore the benefits of submitting your next research article: http://bit.ly/1rmVcio
RESEARCH HIGHLIGHTS Top Targeted therapies: DNA polymerase θ—a new target for synthetic lethality? Published online: 17 February 2015 p125 | doi:10.1038/nrclinonc.2015.23 PDF Gastrointestinal cancer: ADAM8 provides new hope in pancreatic cancer Published online: 10 February 2015 p126 | doi:10.1038/nrclinonc.2015.22 PDF Genetics: BCL11A—targeting triple-negative breast cancer? Published online: 27 January 2015 p127 | doi:10.1038/nrclinonc.2015.10 PDF Targeted therapies: LUX-Lung trials—not all mutations are created equal Published online: 27 January 2015 p127 | doi:10.1038/nrclinonc.2015.9 PDF Pancreatic cancer: Vaccine is safe and improves survival Published online: 03 February 2015 p128 | doi:10.1038/nrclinonc.2015.11 PDF Urological cancer: Abiraterone treatment improves overall survival in patients with mCRPC Published online: 03 February 2015 p128 | doi:10.1038/nrclinonc.2015.14 PDF CNS cancer: Periostin—a new potential target for the treatment of glioblastoma Published online: 03 February 2015 p128 | doi:10.1038/nrclinonc.2015.15 PDF IN BRIEF Haematological cancer:Ibrutinib is efficacious in CLL with TP53 aberrations | Breast cancer: Trastuzumab therapy for small, HER2-positive breast tumours | Haematological cancer: Modifying Hodgkin lymphoma therapy—omission impossiblePDF Clinical Oncology JOBS of the week Director of Neuro-Oncology Research, Children's Center for Cancer & Blood Diseases, Children's Hospital Los Angeles Children's Hospital Los Angeles Postdoctoral Fellowship-Molecular Oncology Moffitt Cancer Center & Research Institute Research Fellowship - Pediatric Oncology Massachusetts General Hospital & Harvard Medical School Postdoctoral Position in Molecular Oncology and Therapeutics University of Kentucky College of Medicine Research Scientists Cancer Research UK - MedImmune Alliance More Science jobs from Clinical Oncology EVENT 2015 Scientific Conference - Pediatric Oncology 09.11.15 Fort Lauderdale, USA More science events from
NEWS AND VIEWS
Surgery: Palliative primary tumour resection in mCRC—debate continues Cornelis J. H. van de VeldePublished online: 20 January 2015 p129 | doi:10.1038/nrclinonc.2015.7Debate continues regarding the benefit of primary tumour resection for patients with asymptomatic metastatic colorectal cancer; the largest observational study conducted to date has demonstrated prolonged survival, but was probably subject to biases, and data from previous meta-analyses of observational data are contradictory. The results of two ongoing randomized trials are eagerly awaited. In the meantime, treatment should be directed at symptom palliation. Full Text | PDF
Urological cancer: Towards rational post-nephrectomy follow-up guidelines in RCC Jean-Jacques Patard & Bernard EscudierPublished online: 10 February 2015 p131 | doi:10.1038/nrclinonc.2015.17Current guidelines recommend up to 5 years of follow-up assessment for patients with localized renal cell carcinoma treated by nephrectomy; however, the recommendations are supported only by low-level evidence, and a recent study suggests considerably prolonged follow up is needed. Thus, approaches to follow-up imaging assessments and their actual benefit on disease outcome require further clarification. Full Text | PDF
Biomarkers: Exceptional responders—discovering predictive biomarkers Naoko Takebe, Lisa McShane & Barbara ConleyPublished online: 17 February 2015 p132 | doi:10.1038/nrclinonc.2015.19Modern genomics technologies enable the identification of genetic alterations, even those present at a low frequency, and can contribute to unveiling the mechanistic rationale behind the unexpected clinical response of 'exceptional responders'. This approach will drive the identification of molecular biomarkers that can be integrated into clinical trials and predict response to a specific therapy. Full Text | PDF
CORRECTION
Redefining the primary objective of phase I oncology trials Mark J. RatainPublished online: 09 September 2014 p126 | doi:10.1038/nrclinonc.2014.157 Full Text | PDF
REVIEWS
Developing biomarker-specific end points in lung cancer clinical trials Joel W. Neal, Justin F. Gainor & Alice T. ShawPublished online: 23 December 2014 p135 | doi:10.1038/nrclinonc.2014.222The classical end points—overall survival, progression-free survival, and response rate—used in cancer clinical trials have important limitations that not only increase the cost and duration of the drug development process, but can also confound establishment of a statistically significant clinical benefit. This Review discusses these issues, and highlights the urgent need for biomarker-based end points, focusing on those that are under investigations in lung cancer, that closely correlate with disease outcomes and that, therefore, hold promise as surrogates for traditional clinical end points. Abstract | Full Text | PDF
Management of locally advanced breast cancer—perspectives and future directions Konstantinos Tryfonidis, Elzbieta Senkus, Maria J. Cardoso & Fatima CardosoPublished online: 10 February 2015 p147 | doi:10.1038/nrclinonc.2015.13Locally advanced breast cancer (LABC) constitutes a heterogeneous entity that includes advanced-stage primary tumours, cancers with extensive nodal involvement and inflammatory breast carcinomas—inoperable cancers with an unfavourable prognosis. The optimal management of LABC requires a multidisciplinary approach consisting of a well-coordinated treatment schedule and close cooperation between medical, surgical and radiation oncologists. In this Review, the authors discuss the current state of the art and possible future treatment strategies for patients with LABC. Abstract | Full Text | PDF
Advances in umbilical cord blood manipulation—from niche to bedside Troy C. Lund, Anthony E. Boitano, Colleen S. Delaney, Elizabeth J. Shpall & John E. WagnerPublished online: 16 December 2014 p163 | doi:10.1038/nrclinonc.2014.215The use of umbilical cord blood (UCB) as source of haematopoietic cell is becoming a mainstay treatment for several diseases. Its principal limitation is the low number of haematopoietic stem and progenitor cells (HSPC), which leads to prolonged engraftment times. The two main approaches to improve UCB engraftment have been to expand HSPC ex vivo before transplantation, or to augment HSPC homing. This Review focuses on approaches and clinical trials aimed at realizing these strategies. Abstract | Full Text | PDF
Image-guided ablation of primary liver and renal tumours David J. Breen & Riccardo LencioniPublished online: 20 January 2015 p175 | doi:10.1038/nrclinonc.2014.237The use of image-guided ablation techniques—including radiofrequency and microwave ablation, cryoablation, and irreversible electroporation—is increasing, predominantly in the treatment of small hepatic and renal tumours (<5 cm). This Review describes the technical considerations for the various ablation modalities. In addition, the authors review the evidence that supports the clinical application of these minimally invasive techniques for the treatment of liver and kidney cancers, and discuss their potential as the standard-of-care first-line treatment, particularly for small, early stage tumours. Abstract | Full Text | PDF
Advertisement
Nature Reviews Clinical Oncology Focus on Paediatric cancer Paediatric oncology is a bustling field with a wide remit, from genomic studies to surgical innovations. This Focus issue aims to look at a number of the key issues, and the cutting-edge research, surrounding treating arguably our most vulnerable patients. Produced with support of a grant from Bristol-Myers Squibb
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com  More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.